Disease · HP_0000579

Nasolacrimal duct obstruction

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Nasolacrimal duct obstruction. Diseases, record HP_0000579. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0000579

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Nasolacrimal duct obstruction
Open Targets ID: HP_0000579
Other names: Blocked tear duct, Lacrimal duct obstruction
Highest stage of its drugs: Phase 1, for 1 of its 11 drugs, from ClinicalTrials.gov

Source Open Targets

Drugs11

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BESIFLOXACIN	CHEMBL1201760	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
ACETAMINOPHEN	CHEMBL112	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
ATRACURIUM BESYLATE	CHEMBL1200527	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
BUPIVACAINE	CHEMBL1098	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
DEXMEDETOMIDINE	CHEMBL778	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
FENTANYL	CHEMBL596	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
LABETALOL	CHEMBL429	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
NITROGLYCERIN	CHEMBL730	Small molecule	Unknown	ClinicalTrials.gov	1	1	0	Drugs and targets
PROPOFOL	CHEMBL526	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
SEVOFLURANE	CHEMBL1200694	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 11

See all 11 drugs

Targets46

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRA2A	Adrenergic receptor	2	Adrenergic receptor alpha-2 agonist; Adrenergic receptor antagonist	Unknown	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor	2	Adrenergic receptor alpha-2 agonist; Adrenergic receptor antagonist	Unknown	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor	2	Adrenergic receptor alpha-2 agonist; Adrenergic receptor antagonist	Unknown	https://conductscience.org/library/genes/152	Drugs and targets
GABRA1	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2560	Drugs and targets

1 to 10 of 46

See all 46 targets

Trials3

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01431170	Safety and Efficacy Study of Besivance™ for Treatment of Congenital Nasolacrimal Duct Obstruction in Children	Phase 1	24	2016-06-09	Congenital Nasolacrimal Duct Obstruction	BESIFLOXACIN	Its record names the disease	ClinicalTrials.gov
NCT05241054	Effect of Local Anesthesia Versus Induced Hypotensive Anesthesia on Quality of External Dacryocystorhinostomy Operation	Not applicable	64		Patient With Nasolacrimal Duct Obstruction, External Dacryocystorhinostomy Operation	ACETAMINOPHEN, ATRACURIUM BESYLATE, BUPIVACAINE, FENTANYL, PROPOFOL, SEVOFLURANE	Its record names the disease	ClinicalTrials.gov
NCT06346561	The Efficacy of Dexmedetomidine Versus Labetalol In Providing Controlled Hypotension In Dacryocystorhinostomy SurgeryA Comparative Randomized Prospective Study	Not applicable	50		Nasolacrimal Duct Obstruction	DEXMEDETOMIDINE, LABETALOL	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Besivance Treatment Group vs Polytrim Treatment Group: serious adverse events	0 of 9	0 of 11	20	NCT01431170

Source Trial comparisons

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0000579

GET https://conductscience.org/api/diseases/v1/HP_0000579/targets?page=2

API reference For AI assistants